Previous 10 | Next 10 |
home / stock / dbvtf / dbvtf news
Montrouge, France, October 31, 2023 DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results DBV has received written feedback from the U.S. Food and Drug Administration (FDA) clarif...
Montrouge, France, October 27, 2023 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the...
2023-10-16 03:29:26 ET More on DBV Technologies: Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies Financial information for DBV Technologies For further details see: DBV Technologies appoints Virginie B...
Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the a...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 00...
2023-07-31 20:02:16 ET DBV Technologies S.A. (DBVT) Q2 2023 Earnings Call July 31, 2023 17:00 PM ET Company Participants Katie Matthews - Head of Investor Relations Daniel Tassé - Chief Executive Officer Sébastien Robitaille - Chief Financial Officer ...
Montrouge, France, July 31, 2023 DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Stud ies and Reports Second Quarter and Half-Year 2023 Financial Results R eceived feedback...
Montrouge, France, July 25, 2023 DBV Technologies to Report First Half 202 3 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical com...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR ...
News, Short Squeeze, Breakout and More Instantly...
Dbv Techs Boulogne Bill Company Name:
DBVTF Stock Symbol:
OTCMKTS Market:
Dbv Techs Boulogne Bill Website:
Châtillon, France, June 5, 2024 DBV Technologies to Participate in the Goldman Sachs 45 th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa...
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 *...
Châtillon, France, May 30, 2024 DBV Technologies to Participate in Upcoming EAACI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food alle...